APLS
Apellis Pharmaceuticals, Inc.Price
Daily candles with volume.
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells since May 14. Recent filings are awards, exercises and tax withholding.
- InstitutionsBEARISH
Q2 2026: 0 added (0 new), 49 trimmed or exited.
- EstimatesRISING
Current-quarter EPS estimate −$0.353 → −$0.318 over 90 days. 0 up, 2 down in 30 days.
- Short sellersCOVERING
Short interest −24.5% to 10.75M shares. 3.1 days to cover.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | EXIT | $0.00 |
| JPMORGAN CHASE & CO | EXIT | $0.00 |
| DIMENSIONAL FUND ADVISORS LP | EXIT | $0.00 |
| MORGAN STANLEY | EXIT | $0.00 |
| BANK OF AMERICA CORP /DE/ | EXIT | $0.00 |
| GOLDMAN SACHS GROUP INC | EXIT | $0.00 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | EXIT | $0.00 |
| UBS Group AG | EXIT | $0.00 |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
Last action Oct 2024| Date | Firm | Rating |
|---|---|---|
| Oct 16, 2024 | Scotiabank INITIATE | Sector Perform |
| Oct 16, 2024 | William Blair INITIATE | Outperform |
| Sep 24, 2024 | Wells Fargo MAINTAIN | Equal-Weight |
| Sep 23, 2024 | Baird MAINTAIN | Outperform |
| Sep 20, 2024 | Mizuho MAINTAIN | Neutral |
| Sep 20, 2024 | Needham REITERATE | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Watson David O. General Counsel May 14, 2026 | TO ISSUER | 11,874 sh |
Watson David O. General Counsel May 14, 2026 | TO ISSUER | 6,001 sh |
Watson David O. General Counsel May 14, 2026 | TO ISSUER | 7,363 sh |
Watson David O. General Counsel May 14, 2026 | TO ISSUER | 14,000 sh |
Watson David O. General Counsel May 14, 2026 | TO ISSUER | 50,974 sh |
Watson David O. General Counsel May 14, 2026 | TO ISSUER | 38,250 sh |
Watson David O. General Counsel May 14, 2026 | TO ISSUER | 45,000 sh |
Watson David O. General Counsel May 14, 2026 | TO ISSUER | 37,708 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.32 | -$0.49–-$0.16 | +3.5% | $209.9M |
| Next Q | -$0.28 | -$0.60–-$0.10 | -6.2% | $219.2M |
| Next FY | -$0.31 | -$2.02–$0.68 | -28.7% | $1.0B |
| Current FY | -$1.17 | -$2.19–-$0.38 | -4.1% | $924.9M |
Short side
FINRA· Apr 30, 2026SecBot reports
5 filings · 1 bullish · 0 bearish · 1 mixed · 3 neutral- NEUTRAL 15-12GMay 26, 2026
Apellis Pharmaceuticals filed Form 15-12G to terminate its SEC registration and suspend reporting…
No further trading action required, APLS shares are no longer publicly traded. Monitor CVR-related events for Biogen's acquisition consideration.
- NEUTRAL 25-NSEMay 14, 2026
Nasdaq filed a Form 25-NSE to remove Apellis Pharmaceuticals' common stock from listing and…
The delisting is a routine administrative step following the completed acquisition. No further trading action is possible in APLS common stock. Monitor CVR milestone payments tied to SYFOVRE sales…
- BULLISH 8-KMay 14, 2026
Biogen completed its acquisition of Apellis Pharmaceuticals on May 14, 2026, through a tender…
The acquisition is complete, APLS shares are delisted and no longer trade. Holders who tendered will receive $41.00 cash plus CVRs. The CVRs are non-transferable and trade only via limited…
- NEUTRAL 8-KMay 4, 2026
Apellis Pharmaceuticals amended its Executive Separation Benefits and Retention Plan in connection…
No immediate trading signal. Monitor the merger timeline and any regulatory or shareholder approvals for Biogen's acquisition of Apellis.
All APLS filing & press-release reports (5)
- 15-12G reportMay 26, 2026
- 25-NSE reportMay 14, 2026
- 8-K reportMay 14, 2026
- 8-K reportMay 4, 2026
- INST-CLUSTER reportMar 27, 2026